Fig. 1From: Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and designIMAGINE study design. BL, baseline; cAMR, chronic active antibody-mediated rejection; EOS, end of study; eGFR, estimated glomerular filtration rate; Q4W, once every 4 weeks; SC, subcutaneousBack to article page